FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vaccine patents



      
           
This page is updated frequently with new Vaccine-related patent applications. Subscribe to the Vaccine RSS feed to automatically get the update: related Vaccine RSS feeds. RSS updates for this page: Vaccine RSS RSS


Date/App# patent app List of recent Vaccine-related patents
10/23/14
20140316122
 Hepatitis b virus vaccines patent thumbnailHepatitis b virus vaccines
This document provides methods and materials for producing immune responses against hepatitis b viruses. For example, polypeptides, nucleic acid molecules encoding such polypeptides, virus-like particles containing such polypeptides, vaccine preparations containing one or more polypeptides provided herein, vaccine preparations containing one or more nucleic acid molecules provided herein, vaccine preparations containing one or more virus-like particles provided herein, and methods for inducing immune responses against hepatitis b viruses within mammals (e.g., humans) are provided..
10/23/14
20140316111
 Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines patent thumbnailChemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (cppt), 1-cyanoimidazole (1-ci), 1-cyanobenzotriazole (1-cbt), or 2-cyanopyridazine-3(2h)one (2-cpo), or a functional derivative or modification thereof.
10/23/14
20140316110
 Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines patent thumbnailChemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (cppt), 1-cyano-imidazole (1-ci), 1-cyanobenzotriazole (1-cbt), or 2-cyanopyridazine-3(2h)one (2-cpo), or a functional derivative or modification thereof.
10/23/14
20140314858
 Ipnv-isav bivalent vaccine using a virus-like particle-based platform and methods of using the same patent thumbnailIpnv-isav bivalent vaccine using a virus-like particle-based platform and methods of using the same
The present invention provides bivalent oral vaccines against infectious pancreatic necrosis virus (ipnv) and infectious salmon anemia virus (isav). Yeast cells comprise an expression vector comprising (i) a polynucleotide sequence encoding a vp2 capsid protein of ipnv and (ii) a polynucleotide sequence encoding one or more antigenic epitopes of hemaglutinin of isav.
10/23/14
20140314839
 Controlled-release peptide compositions and uses thereof patent thumbnailControlled-release peptide compositions and uses thereof
Controlled-release formulations of carboxy-terminal c5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a c5a receptor, are provided.. .
10/23/14
20140314814
 Antigen presenting cancer vaccine patent thumbnailAntigen presenting cancer vaccine
The disclosure provides reagents, methods, and kits, for treating melanoma. The reagent encompasses interferon-gamma (ifn-gamma) responsive melanoma cells, where the cells are autophagic and non-apoptotic melanoma cells, and where the cells express mhc class if.
10/23/14
20140314813
 Clostridium difficile lipoteichoic acid and uses thereof patent thumbnailClostridium difficile lipoteichoic acid and uses thereof
A novel lipoteichoic acid (lta) was isolated from c. Difficile, the structure of which is illustrated below wherein n is an integer between 1 and 20, r3 and r4 are independently selected from c 14:0, c 16:0, c 16:1, c 18:0 or c18:1 fatty acid or any combination thereof wherein one of cor3 or cor4 may be replaced by h.
10/23/14
20140314812
 Live, attenuated streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease patent thumbnailLive, attenuated streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease
The present invention is an attenuated mutant strain of streptococcus pneumonia that has a mutation in the ftsy gene. Vaccines, kits and methods for protecting a subject against streptococcus pneumonia disease or colonization using the attenuated mutant strain are also provided..
10/23/14
20140314811
 Herpes simplex virus vaccines patent thumbnailHerpes simplex virus vaccines
The present invention is directed to herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.. .
10/23/14
20140314810
 Compositions containing purine and pyrimidine nucleosides, peptides, and manganese and their uses patent thumbnailCompositions containing purine and pyrimidine nucleosides, peptides, and manganese and their uses
The invention provides methods of producing vaccines directed against methicillin-resistant staphylococcus aureus (mrsa) or venezuelan equine encephalitis virus (veev), with the methods comprising culturing, harvesting and/or suspending the mrsa or veev in the presence of a radiation-protective composition and irradiating the mrsa with a dose of radiation sufficient to render the mrsa or veev replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide..
10/23/14
20140314808
Infectious cdna clone of european prrs virus and uses thereof
The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the genome of an infectious genotype i (eu) prrs virus clone useful for studying porcine reproductive and respiratory syndrome (prrs), a viral disease affecting swine, and in the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of prrs.. .
10/23/14
20140314807
Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
The present invention relates to compositions comprising replication defective schmallenberg virus vaccines, methods of producing the vaccines, and the administration of such vaccines to animals, including ovines and bovines. The invention further relates to methods for providing long-term protective immunity against schmallenberg in animals, including ovines and bovines..
10/23/14
20140314806
Potency test for vaccine formulations
The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine.
10/23/14
20140314801
Vaccines and methods to treat lyme disease in dogs
The instant invention provides an immunogenic composition comprising an antigenic fragment of ospa protein of borrelia burgdorferi and a chimeric protein containing antigenic fragments of different phylotypes of ospc protein of borrelia burgdorferi. Vaccines incorporating the immunogenic composition of the invention, as well as methods of preventing lyme disease in dogs and/or protecting dogs from lyme disease using the vaccines are also provided..
10/23/14
20140314799
Methods, agents and peptides for inhibiting matrix metalloproteinase-2 signaling
Screening assays and methods of using same for screening to identify modulator agents or compounds that affect matrix metalloproteinase-2 (mmp-2) mediated activation of toll-like receptor-2 (tlr-2) are described herein. Pharmaceutical and immunogenic compositions comprising agents or compounds that modulate mmp-2 mediated activation of tlr-2 are also encompassed.
10/23/14
20140314797
Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose
Lower eukaryotic host cells have been engineered to produce glycoprotein having at least one terminal α-galactosyl epitope. The glycoproteins are useful for the production of highly antigenic glycoprotein compositions with advantages for the production of vaccines..
10/23/14
20140314739
Vaccine adjuvant composition comprising inulin particles
The present invention provides a composition comprising or consisting of inulin particles for use in the reduction or inhibition of inflammation, and/or for treating or preventing inflammatory disease, in a subject. Also provided is a pharmaceutically acceptable composition comprising: particles of inulin; and a substance comprising or consisting of one or more pathogen-associated molecular patterns (pamps), or an equivalent kit of parts, and methods and uses of the composition and kit for inducing or modulating an immune response in a subject, such as modulating an immune response to an antigen or allergen and/or as a vaccine.
10/23/14
20140314709
Il-2 derivatives polypeptides with agonist activity for therapy of cancer and chronic infections
The present invention relates to polypeptides which share primary sequence with human il-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory t cells (t cd4+cd25+foxp3+) and make them more effective in the therapy of murine transplantable tumors.
10/23/14
20140314704
Treatment of b cell lymphomas
Controlled-release formulations of carboxy-terminal c5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a c5a receptor, are provided.. .
10/23/14
20140314653
Method for preparation of aluminum hydroxyphosphate adjuvant
The present invention relates to methods for preparing amorphous aluminum hydroxyphosphate. An aluminum salt and a phosphate solution are co-mixed at a constant ratio in the presence of a buffer.
10/16/14
20140308703
Mammalian cell lines for increasing longevity and protein yield from a cell culture
Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis.
10/16/14
20140308316
Antigen presenting cancer vaccine with gamma interferon
The disclosure provides reagents, methods, and kits, for treating melanoma. The reagent encompasses interferon-gamma (ifn-gamma) responsive melanoma cells, where the cells are autophagic and non-apoptotic melanoma cells, and where the cells express mhc.
10/16/14
20140308307
Influenza a virus vaccines and inhibitors
The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (cpsf30) binding site on the surface of the influenza a non-structural protein 1 (ns1). Specifically, critical biochemical reagents, conditions for crystallization and nmr analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza a (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development..
10/16/14
20140308305
Yeast-based vaccines as immunotherapy
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed..
10/09/14
20140303171
Hiv protease inhibitors
Compounds of formula i are disclosed: wherein a, r1, r2, r3, r4a, r4b, r5, r6 and r7 are defined herein. The compounds encompassed by formula i include compounds which are hiv protease inhibitors.
10/09/14
20140302517
Anti-idiotype antibody against anti-c-met antibody
Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-met antibody, the use of the anti-idiotype antibody for detecting the anti-c-met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto.. .
10/09/14
20140302489
Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof
The invention relates to a polypeptide of a protective antigenic determinant (pad polypeptide) of porcine reproductive and respiratory syndrome virus (prrsv) and nucleic acids encoding a pad polypeptide. The pad polypeptide and nucleic acids encoding a pad polypeptide are useful in the development of antibodies directed to pad, vaccines effective in providing protection against prrsv infection, and diagnostic assays detecting the presence of pad antibodies generated by a pad-specific vaccine.
10/09/14
20140302124
Cytotoxic t lymphocyte inducing immunogens for prevention treatment and diagnosis of influenza virus infection
Influenza virus infection and the resulting complications are a significant global public health problem and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Improving humoral immunity to influenza is the target of current conventional influenza vaccines, however, these are generally not cross-protective.
10/09/14
20140302120
Conjugates of synthetic tlr agonists and uses therefor
The invention provides tlr agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.. .
10/09/14
20140302098
Yeast-based vaccines as immunotherapy
Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed..
10/09/14
20140302088
Compositions and methods for dengue virus chimeric constructs in vaccines
Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition.
10/09/14
20140302087
Manufacture of vaccines that contain both hepatitis b virus surface antigen and surfactant
When preparing hbsag for use in a combination vaccine, it is known to add a non-ionic detergent after the hbsag has been purified. Adding detergents after purification of hbsag is not optimal, however, as it requires a separate processing step during manufacture.
10/09/14
20140302084
Immunogenic protein conjugates and method for making and using the same
Production of protein conjugate vaccines by use of transpeptidase enzymes, such as sortase enzymes. For example, homogenous immunoconjugates (e.g., a population of molecules having the same structure) formed by conjugating an antigenic polypeptide and a bacterial capsule component are provided.
10/09/14
20140302080
Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
The invention features stabilized human immunodeficiency virus (hiv) envelope (env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized hiv env trimers.
10/09/14
20140302079
Novel influenza hemagglutinin protein-based vaccines
Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface.
10/09/14
20140302078
Haemophilus influenzae type b
Polypeptides comprising various amino acid sequences derived from haemophilus influenzae type b, including a number of lipoproteins. These can be used in the development of vaccines for preventing and/or treating bacterial meningitis.
10/09/14
20140302063
Influenza virus antibody compositions
The present invention relates to unique cdr3 amino acid sequences, and to antibodies comprising said sequences. Also provided are therapeutic applications of said antibodies for use in treating or preventing influenza infection, diagnostic applications of said antibodies for use in detecting influenza virus, potency testing of influenza virus vaccines, and screening applications of said antibodies for use in designing a universal influenza vaccine..
10/02/14
20140296824
Apparatus and methods for self-administration of vaccines and other medicaments
A medicament delivery device includes a housing, a medicament container disposed within the housing, an activation mechanism, a cover and an electronic circuit system. The activation mechanism includes an energy storage member configured to produce a force to deliver the dose of a medicament and/or vaccine.
10/02/14
20140296504
Hepatitis b viral variants with reduced susceptibility to nucleoside analogs and uses thereof
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis b virus (hbv) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies.
10/02/14
20140296464
Chromatography medium
The present invention provides a chromatography medium comprising one or more electrospun polymer nanofibres which form a stationary phase comprising a plurality of pores through which a mobile phase can permeate and use of the same in chromatography, such as the isolation of recombinant proteins, monoclonal antibodies, viral vaccines and plasmid dna. The invention further provides for the use of the chromatographic medium in a simulated moving bed system..
10/02/14
20140295409
Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
The present invention provides an isolated mammalian negative strand rna virus, metapneumovirus (mpv), within the sub-family pneumoviridae, of the family paramyxoviridae. The invention also provides isolated mammalian negative strand rna viruses identifiable as phylogenetically corresponding or relating to the genus metapneumovirus and components thereof.
10/02/14
20140294930
Streptococcal glcnac-lacking glycopolypeptides, cell wall carbohydrates, streptococcus vaccines, and methods for making and using them
In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating group a streptococcus (gas), group c streptococcus (gcs), or group a streptococcus (ggs), infections, or other pathogenic streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a streptococcal infection, e.g., group a streptococcus (gas), group c streptococcus (gcs), or group a streptococcus (ggs), infections, or other pathogenic streptococcus infections..
10/02/14
20140294919
Vaccines
The present invention relates to efficient devices for administration of pharmaceutical agents into the skin of the human body. In particular the present invention provides devices for vaccination into the skin.
10/02/14
20140294895
Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines
Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts.
10/02/14
20140294893
Recombinant nonpathogenic mdv vector providing multivalent immunity
The present invention relates to the field of veterinary vaccines, in particular to that of vector vaccines for poultry based on recombinant nonpathogenic marek's disease virus (npmdv). The recombinant npmdv of the invention expresses stably and effectively two heterologous genes each originating from a different micro-organism: the fusion protein gene from newcastle disease virus, and the viral protein 2 gene from infectious bursal disease virus.
10/02/14
20140294892
Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
The present invention relates to attenuated, immunogenic west nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated west nile virus vaccines.. .
10/02/14
20140294890
Recombinant adenovirus vaccines
Recombinant adenovirus vaccines comprising recombinant adenoviruses whose hexon, fiber or protein ix capsid proteins are engineered to include exogenous peptide segments, e.g. Vaccines for human papillomavirus (hpv) and malaria..
10/02/14
20140294889
Use of the pacap as a molecular adjuvant for vaccines
The present invention relates to the use of the pituitary adenylate cyclase activating peptide (pacap) as a molecular adjuvant for vaccines. Among other applications, these vaccines may be used in the protection against infectious agents such as viruses, bacteria and ectoparasites affecting mammals, birds and aquatic organisms.
10/02/14
20140294883
Vaccine
The present invention is concerned with the development of a vaccine against aeromonas hydrophila for use especially in fish. The invention provides an immunogenic s-layer protein of approximately 50 kda of a.
10/02/14
20140294882
Compositions and methods for detecting, treating, and protecting against fusobacterium infection
The present invention relates to protecting against, treating, and detecting fusobacteria infections. Compositions and methods derived from nucleic acid and protein sequences of a 40 kda adhesin protein are provided to protect against, treat, and detect fusobacteria infections in a subject.
10/02/14
20140294879
Modified rsv f proteins and methods of their use
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (f) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rsv infection.. .
10/02/14
20140294876
Amyloid beta 1-6 antigen arrays
The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an aβ1-6 peptide-vlp-composition.
10/02/14
20140294871
Amino acid sequences for controlling pathogens
The present invention relates to antimicrobial peptides, isolated and purified from extracts of tilapia (oreochromis niloticus) gills. Such peptides may be produced by chemical synthesis or by expression in heterologous systems, such as bacteria and yeasts, by conventional molecular biology techniques.
09/25/14
20140287476
Vibrio cholerae 0139 conjugate vaccines
The disclosure pertains to conjugates of the capsular polysaccharide of vibrio cholerae o139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against v.
09/25/14
20140286999
Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
The present invention refers to a pharmaceutical composition containing trifunctional bispecific and/or trispecific antibodies being capable of binding to a specific target antigen(s) for use in a method of immunizing mammals against diseases in which said target antigen(s) is (are) involved, and further to a pharmaceutical composition containing trifunctional bispecific and/or trispecific antibodies being capable of binding to (a) specific target antigen (s) which is (are) involved in a disease of a mammal, specifically a human.. .
09/25/14
20140286996
Modified gram-negative bacteria for use as vaccines
The invention relates to gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the lps of said gram-negative bacteria, wherein said inactivated gene results in the synthesis of a lps having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host..
09/25/14
20140286994
Norovirus vaccine formulations
The present invention relates to antigenic and vaccine compositions comprising norovirus antigens and adjuvants, in particular, mixtures of monovalent vlps and mixtures of multivalent vlps, and to a process for the production of both monovalent and multivalent vlps, the vlps comprising capsid proteins from one or more norovirus genogroups.. .
09/25/14
20140286993
Immune methods against influenza viruses and combinatorial vaccines thereof
The invention provides a method of preventing the spreading of influenza viruses, and the factors making up the said method, and especially provides one type of combinatorial vaccine and the immunization method thereof. Two of more influenza vaccines are inoculated by a certain sequence, and each influenza vaccine vaccines is inoculated at least once, and the inoculation take place two or more times; wherein each influenza vaccine includes one or more antigens, the immunogenic fragments thereof, or the coding genes thereof, and further includes a different antigen, the immunogenic fragments or the coding gene of the different antigen..
09/25/14
20140286985
Simple vaccines from dna launched suicidal flaviviruses
Immunogenic compositions relating to dna launched suicidal flaviviruses and methods of administering the same are described herein.. .
09/25/14
20140286983
Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
Described herein are dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus e-glycoproteins optionally further include mutations that introduce a strong cd4 t cell epitope.
09/25/14
20140286982
Multimeric multiepitope influenza vaccines
An isolated polynucleotide encoding an influenza multi-epitope polypeptide, wherein the multi-epitope polypeptide comprises multiple copies of a plurality of influenza virus peptide epitopes wherein the polypeptide is b(x1zx2z . .
09/25/14
20140286981
Broadly reactive mosaic peptide for influenza vaccine
The invention provides for mosaic influenza virus ha and na sequences and uses thereof.. .
09/25/14
20140286980
Infectious clones of torque teno virus
The present invention is directed to novel nucleotide and amino acid sequences of torque teno virus (“ttv”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine ttv genotypes and isolates.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.3269

4309

3 - 0 - 91